CS1 in Phase II for the treatment of PAH
The drug candidate CS1 is an HDAC inhibitor with a new advanced reformulation of valproic acid (VPA) and acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic, and pressure-relieving properties. CS1 is being developed as a treatment for the rare disease PAH with the aim of offering patients a better and safer disease-modifying drug. CS1’s unique efficacy profile fits well with the pathogenetic mechanisms of the rare disease PAH and is believed to be able to address today’s major unmet need for better treatment alternatives.
CS014 in Phase I
The investigational drug candidate CS014 belongs to Cereno’s HDAC inhibitor program, capitalizing on the principle of epigenetic modulation. CS014 is a new chemical entity and represents a novel approach to antithrombotic treatment without an increased risk of bleeding as documented in preclinical trials.
CS585 in preclinical phase
Drug candidate CS585 is an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Pulmonary Hypertension and thrombosis prevention without increased risk of bleeding.